(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 109.57% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Nuvation Bio's revenue in 2025 is $26,748,000.On average, 10 Wall Street analysts forecast NUVB's revenue for 2025 to be $10,342,256,173, with the lowest NUVB revenue forecast at $6,047,581,758, and the highest NUVB revenue forecast at $16,486,859,793. On average, 10 Wall Street analysts forecast NUVB's revenue for 2026 to be $45,607,131,592, with the lowest NUVB revenue forecast at $9,188,278,838, and the highest NUVB revenue forecast at $75,447,353,600.
In 2027, NUVB is forecast to generate $85,286,673,127 in revenue, with the lowest revenue forecast at $64,675,527,135 and the highest revenue forecast at $103,268,286,688.